Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine for Primary Prevention of Cardiovascular Diseases and Diabetes in Metabolic Syndrome
NCT05105321Phase 4Not yet recruiting
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in metabolic syndrome comparing Placebo Group with Berberine Group (2 arms). Primary endpoint: Rate of composite cardiometabolic endpoints at 3 years. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
berberine
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT05105321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105321.